Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with Tolvaptan

Journal of Cardiac Failure

Volumn 19, Issue 6, 2013, Pages 390-397

  Hauptman, Paul J ^a   Burnett, John ^b   Gheorghiade, Mihai ^c   Grinfeld, Liliana ^d   Konstam, Marvin A ^e   Kostic, Dusan ^f   Krasa, Holly B ^f   Maggioni, Aldo ^g   Ouyang, John ^f   Swedberg, Karl ^h   Zannad, Faiez ⁱ   Zimmer, Chris ^f   Udelson, James E ^e  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^e TUFTS MEDICAL CENTER   (United States)

^f Otsuka Pharmaceutical Development and Commercialization   (United States)

^g ANMCO RESEARCH CENTER   (Italy)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

ⁱ Centre d'Investigations Cliniques   (France)

Author keywords

Heart failure; hyponatremia; prognosis; vasopressin antagonist

Indexed keywords

DIURETIC AGENT; PLACEBO; SODIUM; TOLVAPTAN;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DISEASE COURSE; DYSPNEA; FEMALE; HOSPITAL DISCHARGE; HUMAN; HYPONATREMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME; WEIGHT REDUCTION;

AGED; ANALYSIS OF VARIANCE; ARGININE VASOPRESSIN; BENZAZEPINES; DIURETICS; DYSPNEA; FEMALE; FUROSEMIDE; HEART FAILURE, SYSTOLIC; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RECEPTORS, VASOPRESSIN; WEIGHT LOSS;

EID: 84878580083     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2013.04.001     Document Type: Article

References (23)

1. G.S. Francis, C. Benedict, D.E. Johnstone, P.C. Kirlin, J. Nicklas, and C.S. Liang Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD) Circulation 82 1990 1724 1729
2. L. Klein, C.M. O'Connor, J.D. Leimberger, W. Gattis-Stough, I.L. Pina, G.M. Felker OPTIME-CHF Investigators Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study Circulation 111 2005 2454 2460
3. M. Gheorghiade, W.A. Gattis, C.M. O'Connor, K.F. Adams Jr., U. Elkayam, A. Barbagelata Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial JAMA 291 2004 1963 1971
4. M. Gheorghiade, J.S. Rossi, W. Cotts, D.D. Shin, A.S. Hellkamp, and I.L. Pina Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial Arch Intern Med 167 2007 1998 2005
5. M.A. Konstam, M. Gheorghiade, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, K. Swedberg Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial JAMA 297 2007 1319 1503
6. M. Gheorghiade, W.T. Abraham, N.M. Albert, W. Gattis Stough, B.H. Greenberg, C.M. O'Connor OPTIMIZE-HF Investigators and Coordinators Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry Eur Heart J 28 2007 980 988
7. C. Fraser, and A. Arieff Epidemiology, pathophysiology, and management of hyponatremic encephalopathy Am J Med 102 1997 67 77
8. A. Greenberg Diuretic complications A J Med Sci 319 2000 10 24
9. R.W. Schrier, P. Gross, M. Gheorghiade, T. Berl, J.G. Verbalis, and F.S. Czerwiec Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia N Engl J Med 355 2006 2099 2112
10. J.K. Ghali, M.J. Koren, J.R. Taylor, E. Brooks-Asplund, K. Fan, W.A. Long, and N. Smith Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia J Clin Endocrinol Metab 91 2006 2145 2152
11. P.A. Gross, A. Wagner, and G. Decaux Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet Kidney Int 80 2011 594 600
12. G.T. Jao, and J.R. Chiong Hyponatremia in acute decompensated heart failure: mechanisms, prognosis, and treatment options Clin Cardiol 33 2010 666 671
13. M. Packer, W.H. Lee, P.D. Kessler, N. Medina, M. Yushak, and S.S. Gottlieb Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure J Am Coll Cardiol 10 1987 837 844
14. R. Wald, B.L. Jaber, L.L. Price, A. Upadhyay, and N.E. Madias Impact of hospital-associated hyponatremia on selected outcomes Arch Intern Med 170 2010 294 302
15. S.S. Waikar, D.B. Mount, and G.C. Curhan Mortality after hospitalization with mild, moderate, and severe hyponatremia Am J Med 122 2009 857 865
16. M. Gheorghiade, C. Orlandi, J.C. Burnett, D. Demets, L. Grinfeld, and A. Maggioni Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) J Card Fail 11 2005 260 269
17. M. Gheorghiade, M.A. Konstam, J.C. Burnett Jr., L. Grinfeld, A.P. Maggioni, and K. Swedberg Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials JAMA 297 2007 1332 1343
18. P. van Elteren One the combination of independent two-sample tests of Wilcoxin Bull Int Stat Inst 37 1960 351 361
19. D.S. Lee, P.C. Austin, J.L. Rouleau, P.P. Liu, D. Naimark, and J.V. Tu Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model JAMA 290 2003 2581 2587
20. W.C. Levy, D. Mozaffarian, D.T. Linker, S.C. Sutradhar, S.D. Anker, and A.B. Cropp The Seattle Heart Failure Model: prediction of survival in heart failure Circulation 113 2006 1424 1433
21. P.L. Cyr, K.A. Slawsky, N. Olchanski, H.B. Krasa, T.F. Goss, C. Zimmer, and P.J. Hauptman Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure Am J Health-Sys Pharm 68 2011 328 333
22. M. Gheorghiade, S.S. Gottlieb, J.E. Udelson, M.A. Konstam, F. Czerwiec, J. Ouyang Tolvaptan Investigators Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia Am J Cardiol 97 2006 1064 1067
23. 2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial Circulation 107 2003 2690 2696